Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
indiana blog main
indiana top stories
5
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
biotech
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
fda
roche
blueprint medicines
europe blog main
europe top stories
larotrectinib
loxo oncology
american society of clinical oncology (asco)
amy heimberer
anti-inflammatory drugs
arcturus therapeutics
What
cancer
5
×
drug
5
×
fda
medicine
genetic
address
ahead
alzheimer's
ambien
american
annual
approval
approved
approves
asco
attendees
attention
bad
biotech
blueprint
brain
camp’s
carries
case
cash
certain
chicago
city
clinical
combinations
community’s
days
deeper
designed
disease
dna
doses
eisai
expanding
failed
Language
unset
Current search:
cancer
×
drug
×
" indiana top stories "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More